Back to User profile » Professor Jifeng Feng
Papers published by Professor Jifeng Feng:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
Shen B, Jiang H, Wang L, Qian J, Shu Y, Chen P, Mao G, Liu B, Zhang X, Liu C, Wu J, Li X, Cai W, Shen W, Wang Q, He J, Hua D, Zhang Z, Zhang Y, Feng J
OncoTargets and Therapy 2020, 13:4457-4464
Published Date: 20 May 2020
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/IIG8Om9qlkc/1.jpg)
Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C
OncoTargets and Therapy 2018, 11:8575-8587
Published Date: 30 November 2018
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/PrlTJItshQo/1.jpg)
Lu S, Li W, Zhou C, Hu CP, Qin S, Cheng G, Feng J, Wang J, Cseh A, Peil B, Gibson N, Ehrnrooth E, Zhang L
OncoTargets and Therapy 2018, 11:8565-8573
Published Date: 30 November 2018